Drug safety under the microscope after approval
NCT ID NCT04721106
Summary
This study monitored the safety and effectiveness of the lung cancer drug Vizimpro in real-world patients in Korea after it was approved for use. Doctors observed 188 patients with a specific genetic type of advanced lung cancer who were prescribed the drug as part of their normal care. The goal was to identify any side effects or problems that might occur when the drug is used outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.